S1A
| Resources - ICH Guidances |
S1A: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals:
The tripartite harmonised ICH guideline was finalised (Step 4) in November 1995. This document provides a consistent definition of the circumstances under which it is necessary to undertake carcinogenicity studies on new drugs. These recommendations take into account the known risk factors as well as the intended indications and duration of exposure.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074911.pdf
ICHS1A.pdf
| < Prev | Next > |
|---|
Most Recent Guidances (All Agencies)
- Factors Influencing the Classification of Products at the Device-Drug Interface
- FDA proposes draft guidelines intended to improve the representation of women in medical device clinical studies
- S2 R1
- Good Laboratory Practice for Nonclinical Laboratory Studies
- Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination
